EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion

PHASE2TerminatedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Atrial Fibrillation
Interventions
DRUG

Eplerenone

50 mg per day

DRUG

Placebo

50 mg per day

Trial Locations (2)

66421

Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, Homburg/Saar

NL-9700 RB

Rijksuniversiteit Groningen, Universitair Medisch Centrum, Groningen

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University Medical Center Groningen

OTHER

collaborator

Pfizer

INDUSTRY

lead

University Hospital, Saarland

OTHER